Suppression of tumorigenicity 2 (ST2) is a novel biomarker of CV risk currently utilized for risk stratification and prognostication in patients with heart failure [13] as it provides better discrimination of CV morbidity and mortality compared to cTnT and NT-Pro-BNP [14–17]. This evidence concerns the gene TNNT2 and heart failure.